* Calypte Biomedical Corp., of Berkeley, Calif., entered a collaboration with Trinity Biotech plc, of Dublin, Ireland, for development of a urine HIV test. Financial terms were not disclosed.
* Genta Inc., of San Diego, said the New York-based Aries Fund and Aries Domestic Fund L.P. have agreed to invest $3 million in the company.
* Isis Pharmaceuticals Inc., of Carlsbad, Calif., began a Phase I trial of ISIS 5320 for HIV. The compound inhibits viral replication by blocking HIV's ability to infect immune system cells. The study will evaluate safety and antiviral activity in HIV patients. Results are expected in six months.
* Ostex International Inc., of Seattle, was awarded $6.4 million in damages and attorneys fees in a federal court-ordered arbitration of its breach of contract complaint against Boehringer Mannheim GmbH, of Mannheim, Germany. The dispute centered on a licensing agreement between Boehringer and Ostex for distribution of its Osteomark kits. Boehringer Mannheim is a division of Corange Ltd., of Bermuda.
* Pharmacopeia Inc., of Princeton, N.J. entered a drug discovery collaboration with Zeneca Pharmaceuticals, of Cheshire, U.K. Financial terms were not disclosed. Pharmacopeia will use its combinatorial chemistry to develop libraries of compounds for Zeneca to screen with its biological assays. Zeneca Pharmaceuticals is a division of London-based Zeneca plc.
* Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., received two Phase II Small Business Innovation Research grants totaling $1.06 million from the National Institutes of Health in Bethesda, Md. The funding will be used to develop AIDS drugs. Both products, PRO 542 and PRO 367, are genetically engineered fusion proteins that act like antibodies. The former is designed to inactivate HIV particles and the latter is a radioactive drug aimed at destroying HIV-infected immune system cells.
* Sequana Therapeutics Inc., of La Jolla, Calif., and Memorial Sloan-Kettering Cancer Center, in New York, signed a definitive agreement to create a joint venture for the study of cancer genetics. Sequana and Memorial each initially will contribute $5 million to form a new company, Genos Biosciences Inc. (See BioWorld Today, Aug. 21, 1996 p. 1.)
* Sequus Pharmaceuticals Inc., of Menlo Park, Calif., signed an agreement with Bayer Inc., of Toronto, for marketing Sequus' Amphotec in Canada. The drug, a lipid-based form of amphotericin B, is not yet approved in Canada. Amphotec was cleared by the FDA in November 1996. Bayer Inc. is a subsidiary of Bayer AG, of Leverkusen, Germany.